
Sign up to save your podcasts
Or


Dominik Schumacher, CEO and co-founder of Tubulis GmbH, joins Venrock's Nimish Shah to dive deeper on the company's ADC technology which specifically targets cancer cells thereby reducing side effects on the rest of the body, dramatically improving outcomes and quality of life for patients. They cover how their chemistry sets them apart from similar ADC treatments, what other diseases their breakthrough can target, and how staying data-driven helped him seamlessly move from the lab to leadership.
By Venrock, a venture capital firm4.8
6262 ratings
Dominik Schumacher, CEO and co-founder of Tubulis GmbH, joins Venrock's Nimish Shah to dive deeper on the company's ADC technology which specifically targets cancer cells thereby reducing side effects on the rest of the body, dramatically improving outcomes and quality of life for patients. They cover how their chemistry sets them apart from similar ADC treatments, what other diseases their breakthrough can target, and how staying data-driven helped him seamlessly move from the lab to leadership.

1,298 Listeners

2,682 Listeners

2,463 Listeners

1,103 Listeners

341 Listeners

338 Listeners

388 Listeners

5,673 Listeners

10,213 Listeners

34 Listeners

555 Listeners

21 Listeners

296 Listeners

456 Listeners

1,473 Listeners